RxDoctor Payments Data

David Hendrix

Optometrist · Titusville, FLNPI 1750322871

Payments from drug & device makers

$2,998in general payments, 2019–2025

Across 61 payments — averaging $49.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$572
  • Alcon$428
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$281
  • Sight Sciences, Inc.$227
  • Bausch & Lomb Americas Inc.$223
  • AbbVie$180
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$2,89196%
  • Entertainment$1074%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,998 in reported general payments places this provider in the 80th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$264,550
Medicare patients
938
Services billed
3,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine68$77,195
LumiganBimatoprost56$27,616
XiidraLifitegrast19$25,521
Cyclosporine38$20,520
Brimonidine Tartrate108$10,079
CombiganBrimonidine Tartrate/Timolol22$9,583
SimbrinzaBrinzolamide/Brimonidine Tart16$8,316
CequaCyclosporine11$7,332
Timolol Maleate190$6,125
Latanoprost443$5,692
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat148$3,778
Lotemax SmLoteprednol Etabonate11$3,032
Loteprednol Etabonate22$2,608
Prednisolone Acetate66$2,313
Travoprost11$2,059

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$180$114,394146 claims
Bausch & Lomb Americas Inc.Xiidra$223$25,52119 claims
AlconSimbrinza$428$8,31616 claims
Sun Pharmaceutical Industries Inc.Cequa$146$7,33211 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate$281$5,64033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Titusville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →